Table 3

Adjusted odds ratios for risk of hospitalization by G-CSF
Variable Neutropenia-Related All-Cause
Narrow Definition Broad Definition
OR (95% CI) OR (95% CI) OR (95% CI)
Prophylactic pegfilgrastim (vs. prophylactic filgrastim) 0.43 (0.16–1.13) 0.38 (0.24–0.59) 0.50 (0.35–0.72)
Age 1.01 (0.99–1.03) 1.00 (0.99–1.01) 1.00 (1.00–1.01)
Gender male 0.79 (0.39–1.59) 1.40 (1.03–1.90) 0.94 (0.94–1.18)
Baseline Quan-Charlson comorbidity score 1.02 (0.96–1.14) 1.09 (1.04–1.15) 1.07 (1.03–1.11)
Prior anemia 0.95 (0.57–1.58) 1.30 (1.02–1.66) 1.34 (1.13–1.60)
Breast cancer* 0.28 (0.14–0.56) 0.44 (0.32–0.61) 0.47 (0.38–0.59)
Lung cancer* 0.22 (0.07–0.64) 0.54 (0.37–0.77) 0.84 (0.65–1.08)
Number of myelosuppressive chemotherapy agents 2.28 (1.33–3.89) 0.86 (0.68–1.07) 0.95 (0.81–1.12)

All odds ratios (OR) are adjusted for the other variables listed.

* Compared to NHL, ovarian cancer, and colorectal cancer.

Myelosuppressive chemotherapy agent was defined as one of the following agents: bendamustine, busulfan, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, doxorubicin, epirubicin, etoposide, fludarabine, fluorouracil, hydroxyurea, idarubicin, ifosfamide, irinotecan, ixabepilone, lomustine, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitoxantrone, oxaliplatin, paclitaxel, pemetrexed disodium, procarbazine, temozolomide, teniposide, thiotepa, or topotecan.

Naeim et al.

Naeim et al. BMC Cancer 2013 13:11   doi:10.1186/1471-2407-13-11

Open Data